Financials data is unavailable for this security.
View more
Year on year Getein Biotech Inc 's revenues fell -24.85% from 1.82bn to 1.37bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 498.91m to 279.77m, a -43.92% decrease.
| Gross margin | 67.64% |
|---|---|
| Net profit margin | 20.76% |
| Operating margin | 23.06% |
| Return on assets | 6.73% |
|---|---|
| Return on equity | 9.91% |
| Return on investment | 9.86% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Getein Biotech Inc fell by 157.81m. However, the company earned 333.22m from its operations for a Cash Flow Margin of 24.34%. In addition the company used 356.83m on investing activities and also paid 145.88m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 5.12 |
|---|---|
| Tangible book value per share | 4.70 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.90 |
|---|---|
| Quick ratio | 1.69 |
| Total debt/total equity | 0.2748 |
|---|---|
| Total debt/total capital | 0.205 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -33.33% and -43.71%, respectively. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 1.69% |
|---|---|
| Div growth rate (5 year) | 6.00% |
| Payout ratio (TTM) | 20.05% |
| EPS growth(5 years) | 2.47 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 0.014 |
More ▼
